New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:08 EDTALIM, PSDVpSivida announces resubmission of NDA for ILUVIEN
pSivida Corp. (PSDV) announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration. In the resubmission, pSividas licensee, Alimera Sciences (ALIM), responded to questions raised in the FDAs October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe. Alimera is awaiting the FDAs acceptance of the resubmission and a Prescription Drug User Fee Act date. pSivida will report that information when it becomes available.
News For PSDV;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2015
07:37 EDTALIMAlimera Sciences signs exclusive agreement for distribution of Iluvien in Canada
Alimera Sciences announced that it has signed an exclusive agreement with Knight Therapeutics, a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN, Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use